Does Dual Antibiotic Prophylaxis Better Prevent Surgical Site Infections in Total Joint Arthroplasty?

作者
Amy Sewick,Amun Makani,Chia H. Wu,Judith A. O’Donnell,Keith D. Baldwin,Gwo‐Chin Lee
出处
期刊:Clinical Orthopaedics and Related Research [Lippincott Williams & Wilkins]
卷期号:470 (10): 2702-2707 被引量:134
标识
DOI:10.1007/s11999-012-2255-1
摘要

INTRODUCTION: It is unclear which antibiotic regimen provides the best prophylaxis against surgical site infection (SSI) in patients undergoing hip and knee surgery. QUESTIONS/PURPOSES: Therefore, we determined whether dual antibiotic prophylaxis (1) reduced the rate of SSI compared to single antibiotic prophylaxis and (2) altered the microbiology of SSI. METHODS: We retrospectively reviewed 1828 primary THAs and TKAs performed between September 1, 2008 and December 31, 2010. We divided patients into two groups: (1) those who received a dual prophylactic antibiotic regimen of cefazolin and vancomycin (unless allergy), or (2) received cefazolin (unless allergy) as the sole prophylactic antibiotic. There were 701 males and 1127 females with an average age of 56 years (range, 15–97 years). We limited followup to 1 year, presuming subsequent infections were not related to the initial surgery. RESULTS: During this period, there were 22 SSIs (1.2%). The infection rates for dual antibiotic prophylaxis compared to a single antibiotic regimen were 1.1% and 1.4%, respectively. Of 1328 patients treated with dual antibiotic prophylaxis, only one (0.08%) SSI was culture positive for methicillin resistant Staphylococcus aureus (MRSA), while four of 500 patients (0.8%) receiving only cefazolin prophylaxis had culture positive MRSA infection at the time of reoperation. CONCLUSION: The addition of vancomycin as a prophylactic antibiotic agent apparently did not reduce the rate of SSI compared to cefazolin alone. Use of vancomycin in addition to cefazolin appeared to reduce the incidence of MRSA infections; however, the number needed to treat to prevent a single MRSA infection was very high. LEVEL OF EVIDENCE: Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lwccc完成签到,获得积分10
1秒前
雪满头应助路痴采纳,获得10
1秒前
Nexus应助八级大狂风采纳,获得20
3秒前
7秒前
wangdanhuang完成签到,获得积分10
7秒前
8秒前
9秒前
cz发布了新的文献求助10
10秒前
11秒前
高兴吐司完成签到,获得积分10
12秒前
13秒前
ybk666完成签到,获得积分10
14秒前
科研通AI6.4应助陈一采纳,获得30
14秒前
wulanshu发布了新的文献求助10
14秒前
132456789发布了新的文献求助10
15秒前
16秒前
16秒前
隐形曼青应助qiuqiu815777采纳,获得10
17秒前
IKUN完成签到 ,获得积分10
18秒前
赘婿应助隐形哈密瓜采纳,获得10
18秒前
Akim应助犹豫的归尘采纳,获得10
18秒前
19秒前
20秒前
Panda发布了新的文献求助10
22秒前
22秒前
cc完成签到,获得积分20
24秒前
时尚沅完成签到,获得积分10
24秒前
李鱼丸完成签到,获得积分10
25秒前
26秒前
灵山剑侠完成签到,获得积分10
27秒前
小二郎应助hiipaige采纳,获得10
28秒前
科研通AI6.4应助Yang采纳,获得10
29秒前
29秒前
shriff完成签到,获得积分10
29秒前
30秒前
隐形曼青应助羁鸟采纳,获得70
30秒前
咕咕嘎嘎完成签到,获得积分10
30秒前
shriff发布了新的文献求助10
32秒前
搞怪的凝荷完成签到,获得积分10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
适配Micro-LED色转换的高兼容性量子点负性光刻胶制备与工艺研究 500
Direct and Iterative Linear System Solvers 500
Vander's Renal Physiology第10版 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7309344
求助须知:如何正确求助?哪些是违规求助? 8926457
关于积分的说明 18918577
捐赠科研通 6971579
什么是DOI,文献DOI怎么找? 3212933
关于科研通互助平台的介绍 2381418
邀请新用户注册赠送积分活动 2190758